KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $561.8 million.

  • Jazz Pharmaceuticals' Net Income towards Common Stockholders rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Jazz Pharmaceuticals' Net Income towards Common Stockholders amounted to $561.8 million in FY2024, which was up 34.45% from $417.8 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $561.8 million for FY2024, and its period low was -$329.0 million during FY2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $417.8 million (2023), whereas its average is $255.2 million.
  • In the last 5 years, Jazz Pharmaceuticals' Net Income towards Common Stockholders crashed by 236.17% in 2021 and then spiked by 295.13% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $241.6 million in 2020, then tumbled by 236.17% to -$329.0 million in 2021, then skyrocketed by 34.90% to -$214.1 million in 2022, then spiked by 295.13% to $417.8 million in 2023, then spiked by 34.45% to $561.8 million in 2024.